N/A N=230 Cervical Ripening in Premature Rupture of Membranes
Pregnancy · Premature Rupture of Membranes · Preterm Premature Rupture of Membranes
Primary: Rate of Cesarean Section — 27; 26; 89; 86 participants — p=0.99
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=108 Pitocin or Oral Misoprostol for PROM IOL
PROM
Primary: Time From Induction of Labor (IOL) to Delivery — 18.1; 14.9 Hours
Phase 2 N=21 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Pregnancy Complications
Primary: Number of Participants With Achievement of 34 Weeks Gestation — 0; 0 Participants
Phase 3 N=152 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Preterm Delivery
Primary: Gestational Age at Delivery — 29.2; 29.5 weeks.
N/A N=129 Evaluation of CRB in PROM Patients
Premature Rupture of Fetal Membranes
Primary: Time of Labor — 850.4; 1016.6 Minutes
N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants
N/A N=995 Neonatal Outcome by Reason for Delivery
Preterm Delivery
Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants
Early Phase 1 N=34 PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Methamphetamine-dependence · Postpartum Abstinence
Primary: Successful Recruitment and Randomization of 40 Postpartum Women Into the PROMPT Study — 16; 14; 2; 2 Participants
N/A N=288 Analysis of ROM Plus to Detect Rupture of Membranes
Rupture of Amniotic Membranes
Primary: Pregnant Women Positive and Negative for Membrane Rupture Measured Via Clinical Assessment, Chart Review and ROM Plus — 95; 88; 160; 187 participants
N/A N=175 Preemie Prep For Parents (P3): Home Antenatal Prematurity Education
Premature Birth · Decision Making · Prenatal Care
Primary: Parent Prematurity Knowledge Questionnaire — 30.3; 22.8; 29.3; 25.6 score on a scale
N/A N=104 Improving Cancer On-treatment Symptom Management
Cancer · Thoracic Neoplasms · Gastrointestinal Cancer
Primary: Participants With Change in Their Physician-assessed Burden Score — 43; 32; 25 Participants
N/A N=122 Prevention of Preterm Birth With a Pessary in Singleton Gestations
Preterm Birth · Short Cervix
Primary: Number of Subjects Experiencing Preterm Birth — 26; 23 Participants
Phase 2 N=271 Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Preterm Birth
Primary: Number of Participants Not Giving Birth Before Week 32 and Week 34 of Gestation — 73; 71; 67; 66 Participants
Phase 3 N=200 Prostin and Propess in Induction of Labor
Labor Pain
Primary: Induction to Delivery Interval — 22.3; 21.2 hours
Phase 2 N=30 Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
Pediatric Cancer
Primary: Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments — 88; 12 percentage of participants
Phase 3 N=36 Oral Progesterone for Prevention of Preterm Birth
Preterm Birth
Primary: Rate of Recurrent Preterm Birth — 5; 8 participants
N/A N=385 Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix
Preterm Birth
Primary: Spontaneous Delivery Before 34 Completed Weeks — 51; 12 Participants
Phase 3 N=465 PREGNANT Short Cervix Trial
Preterm Delivery · Short Cervix · Short Uterine Cervical Length
Primary: Number of Participants With Birth <=32 6/7 Weeks Gestation. — 36; 21 participants — p=0.020
N/A N=20 Cervix Monitor for Elasticity and Length Measurements
Preterm Birth
Primary: Cervix Elasticity — 54; 19.7 kPa
N/A N=504 Protecta Smart Analysis Register
Patients With an Indication for an ICD Implantation According to the Guidelines
Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock
N/A N=46 Prevention of Preterm Birth With a Pessary in Twin Gestations
Premature Birth · Short Cervix
Primary: Number of Participants With Preterm Delivery — 9; 8 Participants
N/A N=174 Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Infant, Premature · Premature Birth
Primary: Preterm Birth — 29; 30 Participants
N/A N=144 The Use of Progesterone to Reduce Preterm Birth
Preterm Birth
Primary: Weeks Gestation at Birth Among Patients Receiving the Active Drug. — 31.9; 30.2 weeks
Phase 3 N=1,311 A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
Short Cervical Length
Primary: Number of Participants With Delivery or Fetal Loss of Either Twin Prior to 35 Weeks Gestation — 84; 84; 86 Participants
Phase 3 N=1,708 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
Preterm Birth
Primary: Preterm Birth <35 Weeks Gestation — 66; 122 Participants
N/A N=246 P3 (Prepared, Protected, emPowered)
Sexually Transmitted Diseases · Safe Sex · Adherence, Medication
Primary: PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) — 24; 33; 23; 18 Participants — p=0.04965
Phase 2 N=102 Randomized Trial of Maternal Progesterone Therapy
Congenital Heart Disease · Periventricular Leucomalacia · Brain Development
Primary: Motor Scale of the Bayley Scales of Infant and Toddler Development-III — 90.0; 87.5; 88.7 score on a scale
N/A N=100 PROLONG Prospective, Multi-center, Open-label, Post-market Study
Chronic Pain
Primary: Mean Change in Pain Assessed by Numerical Rating Scale (NRS) From Baseline to 3 Months — 2.3; 3.3 score on a scale
N/A N=87 Multicenter Clinical Observation PROMOS®
Primary and Secondary Omarthrosis
Primary: Radiological and Clinical Loosening Rates of the Glenoid and Humeral Components — 96.29 Percentage survivorship
Phase 3 N=680 Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Trauma
Primary: 24-hour Mortality — 43; 58 participants — p=0.12